Schonfeld Strategic Advisors LLC Immatics N.V. Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.92 - $12.72 $58,690 - $126,106	-9,914 Reduced 9.84%	90,871 $1.05 Million
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $179,378 - $251,236	26,614 Added 35.88%	100,785 $695,000
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $155,517 - $223,714	19,319 Added 35.22%	74,171 $646,000
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $60,245 - $237,705	18,201 Added 49.66%	54,852 $549,000
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $60,312 - $94,187	-10,052 Reduced 21.52%	36,651 $320,000
Q1 2022 May 16, 2022	BUY	$6.64 - $12.85 $2,656 - $5,140	400 Added 0.86%	46,703 $373,000
Q4 2021 Feb 14, 2022	BUY	$10.81 - $14.38 $500,535 - $665,837	46,303 New	46,303 $622,000
Q1 2021 May 17, 2021	SELL	$10.24 - $14.6 $592,640 - $844,975	-57,875 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.67 - $12.05 $3,868 - $4,820	-400 Reduced 0.69%	57,875 $625,000
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $508,740 - $882,866	58,275 New	58,275 $1,000

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.